Should I Buy SER? SER 2026 Analysis

Should You Buy Serina Therapeutics Inc (SER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.680

1 Day change

1.82%

52 Week Range

7.920

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Serina Therapeutics Inc (SER) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows a bearish technical trend, lacks positive trading signals, has no recent news or catalysts, and demonstrates extremely poor financial performance in the latest quarter. Given these factors, the stock is better suited to be avoided at this time.

Technical Analysis

The stock is in a bearish trend with MACD negatively expanding (-0.117), RSI indicating oversold conditions (18.016), and moving averages showing a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.823 and 1.399, with resistance levels at 2.511 and 3.198. Pre-market price is down by -2.35%, further confirming the downward momentum.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

The stock also has a 60% probability of declining -3.98% in the next month based on similar candlestick patterns.

Financial Performance

In Q3 2025, revenue dropped to $0 (-100% YoY), net income fell to -$4,585,000 (-425.18% YoY), and EPS declined to -0.44 (-438.46% YoY). Gross margin remained flat at 100%. Overall, the financial performance is extremely poor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

1 Analyst Rating

Wall Street analysts forecast SER stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.650

Low

Averages

High

Current: 1.650

Low

Averages

High

H.C. Wainwright

Buy

initiated

$15

AI Analysis

2025-07-14

Reason

H.C. Wainwright

Price Target

$15

AI Analysis

2025-07-14

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.

Jones Trading

Justin Walsh

Strong Buy

Initiates

$11

2025-03-11

Reason

Jones Trading

Justin Walsh

Price Target

$11

2025-03-11

Initiates

Strong Buy

Reason

JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug delivery and soon-to-be clinical stage biotech company that went public via a reverse merger with AgeX Therapeutics in March of last year whose lead asset, SER-252, is being developed for the management of motor fluctuations and dyskinesia in patients with advanced Parkinson's Disease. The firm has "high confidence" that SER-252 will at least match the efficacy observed with other apomorphine delivery approaches, such as Supernus' (SUPN) recently approved Onapgo, while delivering improved tolerability and convenience, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SER

Unlock Now

SER Should I Buy

SER Should I Buy

Should You Buy Serina Therapeutics Inc (SER) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch